• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Stick With Intravenous or Give Subcutaneous a Shot? Time and Other Considerations When Evaluating Cancer Drug Formulations.坚持静脉注射还是尝试皮下注射？评估癌症药物制剂时的时间及其他考量因素。
JCO Oncol Pract. 2025 Mar;21(3):267-269. doi: 10.1200/OP-24-00501. Epub 2024 Aug 2.
2
Delivery of intravenous anti-cancer therapy at home versus in hospital or community settings for adults with cancer.成年癌症患者在家中与在医院或社区环境中接受静脉抗癌治疗的情况。
Cochrane Database Syst Rev. 2025 Apr 22;4(4):CD014861. doi: 10.1002/14651858.CD014861.pub2.
3
Bisphosphonates for breast cancer.用于乳腺癌的双膦酸盐类药物。
Cochrane Database Syst Rev. 2005 Jul 20(3):CD003474. doi: 10.1002/14651858.CD003474.pub2.
4
Evaluation of the economic benefits, administration times, and patient preferences associated with the use of biotechnological drugs administered subcutaneously and intravenously in patients with cancer: a systematic review.评估癌症患者皮下和静脉使用生物技术药物的经济效益、管理时间和患者偏好：系统评价。
Expert Rev Pharmacoecon Outcomes Res. 2023 Jul-Dec;23(9):1017-1026. doi: 10.1080/14737167.2023.2249232. Epub 2023 Sep 4.
5
Prescription of Controlled Substances: Benefits and Risks管制药品的处方：益处与风险
6
Subcutaneous unfractionated heparin for the initial treatment of venous thromboembolism.皮下注射普通肝素用于静脉血栓栓塞症的初始治疗。
Cochrane Database Syst Rev. 2017 Feb 14;2(2):CD006771. doi: 10.1002/14651858.CD006771.pub3.
7
Bisphosphonates for breast cancer.用于乳腺癌的双膦酸盐类药物。
Cochrane Database Syst Rev. 2002(1):CD003474. doi: 10.1002/14651858.CD003474.
8
Differences Between Intravenous and Subcutaneous Modes of Administration in Oncology from the Patient, Healthcare Provider, and Healthcare System Perspectives: A Systematic Review.静脉和皮下给药模式在肿瘤学领域从患者、医疗服务提供者和医疗保健系统角度的差异：系统评价。
Adv Ther. 2024 Dec;41(12):4396-4417. doi: 10.1007/s12325-024-02985-9. Epub 2024 Oct 19.
9
Real-World Quantitative Insights into the Treatment Experience of Patients with Cancer in the USA with Subcutaneous Versus Intravenous Drug Delivery.对美国癌症患者皮下给药与静脉给药治疗体验的真实世界定量洞察。
Oncol Ther. 2025 Jul 16. doi: 10.1007/s40487-025-00360-4.
10
Preclinical evaluation of 9-chloro-2-methylellipticinium acetate alone and in combination with conventional anticancer drugs for the treatment of human brain tumor xenografts.单独及与传统抗癌药物联合使用的9-氯-2-甲基玫瑰树碱醋酸盐对人脑肿瘤异种移植瘤治疗的临床前评估。
J Cancer Res Clin Oncol. 1998 Jan;124(1):19-26. doi: 10.1007/s004320050128.

引用本文的文献

1
Correction: Cost of Anti-CD38 Monoclonal Antibodies in Combination With Bortezomib, Lenalidomide and Dexamethasone for the Frontline Treatment of Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma in the US.更正：美国抗CD38单克隆抗体联合硼替佐米、来那度胺和地塞米松用于一线治疗不适合移植的新诊断多发性骨髓瘤患者的成本
J Health Econ Outcomes Res. 2025 Aug 12;12(2):62-66. doi: 10.36469/001c.143106. eCollection 2025.
2
Cost of Anti-CD38 Monoclonal Antibodies in Combination With Bortezomib, Lenalidomide and Dexamethasone for the Frontline Treatment of Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma in the US.抗CD38单克隆抗体联合硼替佐米、来那度胺和地塞米松用于美国新诊断的不适于移植的多发性骨髓瘤患者一线治疗的费用
J Health Econ Outcomes Res. 2025 Jul 21;12(2):27-31. doi: 10.36469/001c.141714. eCollection 2025.

本文引用的文献

1
Subcutaneous Versus Intravenous Amivantamab, Both in Combination With Lazertinib, in Refractory Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: Primary Results From the Phase III PALOMA-3 Study.皮下注射与静脉注射 Amivantamab，均联合 Lazertinib，治疗难治性表皮生长因子受体突变型非小细胞肺癌：III 期 PALOMA-3 研究的主要结果。
J Clin Oncol. 2024 Oct 20;42(30):3593-3605. doi: 10.1200/JCO.24.01001. Epub 2024 Jun 10.
2
Consuming Patients' Days: Time Spent on Ambulatory Appointments by People With Cancer.消耗患者的时间：癌症患者门诊预约所花费的时间
Oncologist. 2024 May 3;29(5):400-406. doi: 10.1093/oncolo/oyae016.
3
Advancing Subcutaneous Dosing Regimens for Biotherapeutics: Clinical Strategies for Expedited Market Access.推进生物疗法的皮下给药方案：加速市场准入的临床策略。
BioDrugs. 2024 Jan;38(1):23-46. doi: 10.1007/s40259-023-00626-1. Epub 2023 Oct 13.
4
Evaluation of the economic benefits, administration times, and patient preferences associated with the use of biotechnological drugs administered subcutaneously and intravenously in patients with cancer: a systematic review.评估癌症患者皮下和静脉使用生物技术药物的经济效益、管理时间和患者偏好：系统评价。
Expert Rev Pharmacoecon Outcomes Res. 2023 Jul-Dec;23(9):1017-1026. doi: 10.1080/14737167.2023.2249232. Epub 2023 Sep 4.
5
A 15 Year Review (2006-2020) of Patient-Reported Outcome (PRO) in United States Oncology Product Labeling and Trends in Sponsor Size and Oncology Experience.美国肿瘤学产品标签中患者报告结局（PRO）的15年回顾（2006 - 2020年）以及申办方规模和肿瘤学经验趋势
Arch Intern Med Res. 2022;5(3):412-419. doi: 10.26502/aimr.0123. Epub 2022 Aug 11.
6
Subcutaneous vs Intravenous Administration of Medications and Fluids for Patients With Cancer in the US and Canada.美国和加拿大癌症患者皮下与静脉给药及输液情况
JAMA Oncol. 2023 May 1;9(5):717-719. doi: 10.1001/jamaoncol.2023.0239.
7
Clinical Administration Characteristics of Subcutaneous and Intravenous Administration of Daratumumab in Patients With Multiple Myeloma at Mayo Clinic Infusion Centers.梅奥诊所输注中心多发性骨髓瘤患者皮下和静脉注射达雷妥尤单抗的临床管理特点。
JCO Oncol Pract. 2023 Apr;19(4):e542-e549. doi: 10.1200/OP.22.00421. Epub 2023 Feb 9.
8
A Systematic Review of Time and Resource Use Costs of Subcutaneous Versus Intravenous Administration of Oncology Biologics in a Hospital Setting.医院环境中皮下注射与静脉注射肿瘤生物制剂的时间和资源使用成本的系统评价
Pharmacoecon Open. 2023 Jan;7(1):3-36. doi: 10.1007/s41669-022-00361-3. Epub 2022 Aug 23.
9
The Time Toxicity of Cancer Treatment.癌症治疗的时间毒性
J Clin Oncol. 2022 May 20;40(15):1611-1615. doi: 10.1200/JCO.21.02810. Epub 2022 Mar 2.
10
White Paper on the Value of Time Savings for Patients and Healthcare Providers of Breast Cancer Therapy: The Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Injection as an Example.《乳腺癌治疗中为患者和医疗保健提供者节省时间的价值白皮书：以曲妥珠单抗和帕妥珠单抗皮下注射固定剂量组合为例》。
Adv Ther. 2022 Feb;39(2):833-844. doi: 10.1007/s12325-021-01996-0. Epub 2022 Jan 5.

坚持静脉注射还是尝试皮下注射？评估癌症药物制剂时的时间及其他考量因素。

Stick With Intravenous or Give Subcutaneous a Shot? Time and Other Considerations When Evaluating Cancer Drug Formulations.

作者信息

Gupta Arjun, Tregear Michelle, Pace Makala B, Vogel Rachel I

机构信息

Divsion of Hematology, Oncology & Transplantation, University of Minnesota, Minneapolis, MN.

National Breast Cancer Coalition, Washington, DC.

出版信息

JCO Oncol Pract. 2025 Mar;21(3):267-269. doi: 10.1200/OP-24-00501. Epub 2024 Aug 2.

DOI:10.1200/OP-24-00501
PMID:39094070
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11787399/
Abstract

Time and other considerations when evaluating a switch to newer drug formulations (eg, subQ vs IV).

摘要

评估更换为更新的药物制剂（如皮下注射与静脉注射）时的时间及其他考量因素。